Candel Therapeutics, Inc. balance sheet

At the end of fiscal 2022, Candel Therapeutics, Inc. had total assets of $77.7m, total liabilities of $30.0m and shareholders' equity of $47.7m. It held $70.1m in cash against $648,000 of debt: net cash of $69.4m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Candel Therapeutics, Inc.: balance sheet, annual
Fiscal year	2020Dec 2020	2021Dec 2021	2022Dec 2022
Cash and equivalents	35	83	70
Total current assets	35	85	72
Total assets	38	89	78
Accounts payable	1	2	0
Total current liabilities	5	5	6
Long-term debt	0	1	—
Total debt	0	1	1
Total liabilities	13	25	30
Shareholders' equity	−24	64	48
Non-controlling interests and other (assets − liabilities − equity)	49	—	—
Net debt (negative = net cash)	−35	−82	−69
Shares outstanding	12m	—	29m

US$ millions unless shown otherwise. Fiscal quarters.

Candel Therapeutics, Inc.: balance sheet, quarterly
Quarter	2021 Q1Mar 2021	2021 Q2Jun 2021	2021 Q3Sept 2021	2021 Q4Dec 2021	2022 Q1Mar 2022	2022 Q2Jun 2022	2022 Q3Sept 2022	2022 Q4Dec 2022
Total current assets	—	24	91	85	96	87	79	72
Total assets	—	31	96	89	102	93	85	78
Accounts payable	—	1	1	2	1	2	1	0
Total current liabilities	—	4	4	5	5	6	6	6
Long-term debt	—	1	1	1	—	—	—	—
Total debt	—	1	1	1	—	—	—	—
Total liabilities	—	25	33	25	38	33	33	30
Shareholders' equity	−27	−43	63	64	64	60	52	48
Non-controlling interests and other (assets − liabilities − equity)	—	49	—	—	—	—	—	—
Shares outstanding	—	12m	29m	29m	29m	29m	29m	29m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Candel Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Candel Therapeutics, Inc.